Rhenman & Partners Asset Management AB decreased its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 65.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 112,741 shares of the company’s stock after selling 217,894 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Pliant Therapeutics were worth $2,042,000 […]
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has received a consensus recommendation of “Buy” from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have issued a report on the stock in […]
HC Wainwright reaffirmed their buy rating on shares of Pliant Therapeutics (NASDAQ:PLRX – Free Report) in a report issued on Wednesday morning, Benzinga reports. The brokerage currently has a $36.00 price target on the stock. A number of other analysts have also recently weighed in on the stock. Oppenheimer raised their target price on shares […]
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has received an average rating of “Buy” from the nine brokerages that are covering the firm, MarketBeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have covered the stock in the last year is […]
Rhenman & Partners Asset Management AB acquired a new stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 330,635 shares of the company’s stock, valued at approximately $5,733,000. Rhenman & Partners Asset Management AB […]